ASO VISUAL ABSTRACT

ASO Visual Abstract: Lymph Node Metastases from Visceral Peritoneal Colorectal Metastases are Associated with Systemic Recurrence

Eran Nizri, MD, PhD^{1,2} , Yaniv Berger, MD^{2,3}, Eraan Green, MD¹, Matan Kyzer, MD^{2,3}, Asaf Aizic, MD⁴, Nadav Nevo, MD¹, Fabian Gerstenhaber, MD¹, Joseph M. Klausner, MD^{1,2}, Mordechai Gutman, MD^{2,3}, Guy Lahat, MD^{1,2}, Aviad Hoffman, MD⁵, and Ravit Geva, MD^{2,6}

¹Department of Surgery A, Peritoneal Surface Malignancy and Melanoma Unit, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel; ²The Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; ³Department of Surgery B, Chaim Sheba Medical Center, Tel Hashomer, Israel; ⁴Institute of Pathology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel; ⁵Department of General Surgery, Rappaport Faculty of Medicine, Technion—Israel Institute of Technology, Haifa, Israel; ⁶Oncology Division, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

Visceral peritoneal colorectal metastases may send metastases to lymph nodes of involved organs. These lymphatic metastases are associated with systemic recurrence (<http://doi.org/10.1245/s10434-021-10869-3>).

Supplementary Information The online version supplementary material available at <https://doi.org/10.1245/s10434-021-10966-3>.

COMPETING INTERESTS Ravit Geva— Honoraria (Self)—BMS, Lilly, Medison, Roche, Novartis, Janssen, Takeda, MSD, Pfizer, MERCK; Advisory/Consultancy—EISAI, Astrazeneca, Bayer, MSD, Novartis, BI. BOL Pharma, Roche; Research Grant/Funding (Institution)—Educational grant to the research unit—Novartis; Travel/Accommodations/Expenses—Merck, Bayer, BMS, Medison; Other; BOL Pharma—options; Pyxis—Medical lead, options

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.